33,433 Becton, Dickinson and Company $BDX Shares Acquired by Assenagon Asset Management S.A.

Key Points

• Assenagon Asset Management increased its Becton, Dickinson and Company stake by 431.3% in the third quarter, acquiring 33,433 additional shares and bringing its holdings to 41,185 shares valued at approximately $7.37 million.
• Institutional investors own 86.97% of BDX shares, while several other funds also increased their positions during the quarter.
• BDX exceeded quarterly earnings and revenue expectations, reporting $3.23 in EPS and $4.98 billion in revenue. Analysts maintain a consensus “Hold” rating with an average price target of $185.07, below the stock’s reported price of $193.77.

Assenagon Asset Management S.A. raised its holdings in shares of Becton, Dickinson and Company (NYSE:BDX - Free Report) by 431.3% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 41,185 shares of the medical instruments supplier's stock after purchasing an additional 33,433 shares during the quarter. Assenagon Asset Management S.A.'s holdings in Becton, Dickinson and Company were worth $7,372,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Maryland Capital Advisors Inc. lifted its holdings in Becton, Dickinson and Company by 13,900.0% during the 3rd quarter. Maryland Capital Advisors Inc. now owns 140 shares of the medical instruments supplier's stock worth $25,000 after purchasing an additional 139 shares in the last quarter. State of Alaska Department of Revenue boosted its holdings in Becton, Dickinson and Company by 10.8% in the 3rd quarter. State of Alaska Department of Revenue now owns 29,913 shares of the medical instruments supplier's stock valued at $5,354,000 after purchasing an additional 2,915 shares during the period. Turtle Creek Wealth Advisors LLC boosted its holdings in Becton, Dickinson and Company by 248.1% in the 3rd quarter. Turtle Creek Wealth Advisors LLC now owns 10,012 shares of the medical instruments supplier's stock valued at $1,792,000 after purchasing an additional 7,136 shares during the period. Fort Washington Investment Advisors Inc. OH grew its position in shares of Becton, Dickinson and Company by 0.5% during the 3rd quarter. Fort Washington Investment Advisors Inc. OH now owns 1,112,958 shares of the medical instruments supplier's stock valued at $199,672,000 after purchasing an additional 5,109 shares in the last quarter. Finally, First Pacific Financial grew its position in shares of Becton, Dickinson and Company by 14.8% during the 3rd quarter. First Pacific Financial now owns 4,736 shares of the medical instruments supplier's stock valued at $876,000 after purchasing an additional 612 shares in the last quarter. Institutional investors own 86.97% of the company's stock.

Becton, Dickinson and Company Price Performance

BDX stock opened at $193.77 on Wednesday. The firm has a 50 day simple moving average of $184.51 and a two-hundred day simple moving average of $164.26. The stock has a market cap of $53.39 billion, a PE ratio of 58.36, a P/E/G ratio of 12.86 and a beta of 0.21. Becton, Dickinson and Company has a one year low of $127.59 and a one year high of $195.99. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.87 and a quick ratio of 0.51.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share for the quarter, beating the consensus estimate of $3.14 by $0.09. The firm had revenue of $4.98 billion for the quarter, compared to analysts' expectations of $4.89 billion. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. The business's quarterly revenue was up 5.4% on a year-over-year basis. During the same quarter last year, the company posted $3.68 EPS. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. On average, analysts predict that Becton, Dickinson and Company will post 12.67 EPS for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Wednesday, September 30th. Investors of record on Wednesday, September 9th were given a $1.05 dividend. The ex-dividend date was Wednesday, September 9th. This represents a $4.20 annualized dividend and a yield of 2.2%. Becton, Dickinson and Company's payout ratio is 126.51%.

Analysts Set New Price Targets

Several research analysts have recently weighed in on BDX shares. Bank of America upped their price target on shares of Becton, Dickinson and Company from $185.00 to $200.00 and gave the stock a "neutral" rating in a report on Monday, August 31st. Barclays began coverage on Becton, Dickinson and Company in a research note on Wednesday, October 7th. They set an "underweight" rating and a $165.00 price objective for the company. Evercore set a $180.00 target price on Becton, Dickinson and Company in a research report on Monday, July 6th. Weiss Ratings upgraded Becton, Dickinson and Company from a "sell (d+)" rating to a "hold (c-)" rating in a research report on Monday, September 28th. Finally, Piper Sandler upped their target price on Becton, Dickinson and Company from $161.00 to $175.00 and gave the stock a "neutral" rating in a research note on Friday, August 7th. Eight equities research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of "Hold" and a consensus price target of $185.07.

Insider Activity at Becton, Dickinson and Company

In related news, EVP Roland Goette sold 2,438 shares of the stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $180.84, for a total value of $440,887.92. Following the transaction, the executive vice president owned 14,856 shares of the company's stock, valued at $2,686,559.04. This represents a 14.10% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Thomas Polen, Jr. sold 4,152 shares of the firm's stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $185.00, for a total value of $768,120.00. Following the sale, the chief executive officer owned 110,163 shares in the company, valued at $20,380,155. The trade was a 3.63% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 6,906 shares of company stock valued at $1,265,855 over the last 90 days. 0.40% of the stock is owned by insiders.

About Becton, Dickinson and Company

Becton, Dickinson and Company, commonly known as BD, is a global medical technology company that develops, manufactures and sells a broad range of products used by healthcare providers, clinical laboratories, pharmaceutical companies and patients. Its offerings support medication delivery, diagnostics, infection prevention, surgical care and other clinical procedures.

BD's products include needles, syringes, injection devices, intravenous administration systems, medication-management technologies, specimen-collection products, diagnostic systems and laboratory instruments.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.